Vaxil Initiates Pre-Clinical Study in New Oncology Target
October 13 2020 - 7:30AM
VAXIL BIO LTD. (“
Vaxil” or the
“
Company”) (TSX VENTURE: VXL), an innovative
immunotherapy biotech company specializing in cancer and infectious
diseases, is pleased to announce the initiation of the pre-clinical
program for ImMucin™ in combination with the E-selectin binding
polymer-based therapeutic (“
P-Esbp”), which Vaxil
licensed for development and commercialization from BGN
Technologies, the technology transfer company of Ben-Gurion
University of the Negev, Israel (“
BGU”).
The pre-clinical program will be led by Prof.
Ayelet David from BGU to assess the potential for ImMucin and the
P-Esbp separately and in combination for the treatment of solid
tumors including breast and ovarian cancer.
“We are excited to partner with Vaxil on this
preclinical program and look forward to providing meaningful
results towards advancing this unique therapeutic approach for
arresting cancer, as well as inflammatory diseases,” said Prof.
David.
P-Esbp was invented by Prof. Ayelet David, Head
of the Drug Targeting and Nanomedicine Laboratory, Department of
Clinical Biochemistry and Pharmacology, Prof. Gonen Ashkenasy from
the Department of Chemistry and their joint PhD student, Yosi
Shamay, all from the BGU.
“I am proud to advance our pre-clinical oncology
research program, in conjunction with our research partner Prof.
Ayelet David and her team at Ben Gurion University. I believe we
can have significant impact in cancer immunotherapy. This program
will run over the course of the next year and a half, after which
we will evaluate results and the potential for clinical trials
using ImMucin™ / P-Esbp alone and in combination. We look forward
to working on this oncology program with Prof. David, in addition
to continuing to advance CorVax™, our potential COVID-19 Vaccine,”
said David Goren, Vaxil’s Chairman and Chief Executive Officer, and
continued, “The BGU research will also aim to confirm the potential
of ImMucin™ in oncology care following the successful clinical
trial done several years ago.”
P-Esbp has been shown to interfere with
E-selectin-mediated interactions, thus blocking leukocyte and
cancer cells recruitment to inflamed and cancerous tissues, which
reduced colonization of circulating cancer cells in secondary
organs. In addition, it was also shown to inhibit leukocyte
recruitment and inflammation in animal models of liver injury and
atherosclerosis. These results combined demonstrate the promising
therapeutic potential of E-selectin targeted therapy for inhibiting
inflammation and arresting cancer disease progression as well as
other diseases where inflammation plays a role.
The work performed by Prof. David at BGU will be
supported by the Company’s existing working capital.
Other company updates
Further to our press from September 17, 2020 the
Company wishes to clarify that interest amounting to $2,209 was
converted into 20,086 Common Shares at the market price of the
Common Shares, being $0.11, and not $0.10 as previously
reported.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech
company focused on its novel approach to targeting prominent cancer
markers and infectious diseases. Its lead product ImMucin™
successfully completed a Phase 1/2 clinical trial in multiple
myeloma for which it received orphan drug status from the FDA and
EMA. The company aims to continue to develop ImMucin™, a COVID-19
and a tuberculosis vaccine / treatment that has demonstrated
promising preliminary results with further preclinical evaluation
planned. Additional indications and mAb candidates are under
evaluation as immuno-oncology and infectious disease treatments
alone and in combination with other treatments.
Vaxil exploits the unique properties of signal
peptide domains on crucial proteins to develop targeted therapies
against cancer targets and infectious disease pathogens. These
signal peptide domains are identified by VaxHit™, Vaxil’s
proprietary bioinformatic approach. These signal peptides induce a
robust T- and B-cell response across wide and varied HLA subtypes,
while acting as true, universal neoantigens. The peptide platform
targets these cells by “educating” or specifically activating the
immune system to recognize and attack the affected cells. In
addition, Vaxil’s mAb platform directly recognizes the target
protein expressed on malignant cells and recruits other elements of
the immune system to lyse those cells.
The Company is not making any express or implied
claims that it has completed developing or will be successful in
developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
About BGN Technologies
BGN Technologies is the technology transfer
company of Ben-Gurion University, the third largest university
in Israel. BGN Technologies brings technological innovations from
the lab to the market and fosters research collaborations and
entrepreneurship among researchers and students. To date,
BGN Technologies has established over 100 startup
companies in the fields of biotech, hi-tech, and cleantech,
and has initiated leading technology hubs, incubators, and
accelerators. Over the past decade, BGN Technologies has
focused on creating long-term partnerships with multinational
corporations such as Deutsche Telekom, Dell-EMC, PayPal, and
Lockheed Martin, securing value and growth for Ben-Gurion
University as well as the Negev region. For more information,
visit the BGN Technologies website.
Disclaimer: The Company cautions that COVID-19
Vaccine Development is still under early stage research and
development and is not making any express or implied claims that it
has the ability to eliminate the COVID-19 virus at this time. The
TSX Venture Exchange Inc. has in no way passed upon the merits of
the Company and has neither approved nor disapproved the contents
of this press release. This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors - including the
availability of funds, the results of financing efforts, the
results of exploration activities -- that could cause actual
results to differ materially from the Company's expectations are
disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. This press
release does not constitute an offer to sell or a solicitation of
an offer to sell any of the securities described herein in the
United States or elsewhere. These securities have not been, and
will not be, registered in the United States Securities Act of
1933, as amended, or any state securities laws, and may not be
offered or sold in the United States or to U.S. persons unless
registered or exempt therefrom.
CONTACT INFORMATION For further information
please visit http://vaxil-bio.com/ or contact:David
Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Sep 2023 to Sep 2024